Pramlintide treatment reduces 24-h caloric intake and meal sizes and improves control of eating in obese subjects: a 6-wk translational research study
The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
Evidence from rodent studies indicates that the β-cell-derived neurohormone amylin exerts multiple effects on eating behavior, including reductions in meal size, intake of highly palatable foods, and stress-induced sucrose consumption. To assess the effect of amylin agonism on human eating behavior we conducted a randomized, blinded, placebo-controlled, multicenter study investigating the effects of the amylin analog pramlintide on body weight, 24-h caloric intake, portion sizes, “fast food” intake, and perceived control of eating in 88 obese subjects. After a 2-day placebo lead-in, subjects self-administered pramlintide (180 μg) or placebo by subcutaneous injection 15 min before meals for 6 wk without concomitant lifestyle modifications. Compared with placebo, pramlintide treatment elicited significant mean reductions from baseline in body weight on day 44 (−2.1 ± 0.3 vs. +0.1 ± 0.4%, P < 0.001), 24-h caloric intake (−990 ± 94 vs. −243 ± 126 kcal on day 3, P < 0.0001; −680 ± 86 vs. −191 ± 161 kcal on day 43, P < 0.01), portion sizes, and caloric intake at a “fast food challenge” (−385 ± 61 vs. −109 ± 88 kcal on day 44, P < 0.05). Pramlintide treatment also improved perceived control of eating, as demonstrated by a 45% placebo-corrected reduction in binge eating scores ( P < 0.01). The results of this translational research study confirm in humans various preclinical effects of amylin agonism, demonstrating that pramlintide-mediated weight loss in obese subjects is accompanied by sustained reductions in 24-h food intake, portion sizes, fast food intake, and binge eating tendencies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The three-factor eating questionnaire to measure dietary restraint, disinhibition and hunger
Stunkard, A. J., & Messick, S. (1985) · Journal of Psychosomatic Research · doi:10.1016/0022-3999(85)90010-8 · Cited by 4,687
The assessment of binge eating severity among obese persons
Gormally, J., Black, S., Daston, S., & Rardin, D. (1982) · Addictive Behaviors · doi:10.1016/0306-4603(82)90024-7 · Cited by 2,129
The gut and energy balance: visceral allies in the obesity wars
Badman, M. K., & Flier, J. S. (2005) · Science · doi:10.1126/science.1109951 · Cited by 532
Hollander, P. A., Levy, P., Fineman, M. S., Maggs, D. G., Shen, L. Z., Strobel, S. A., Weyer, C., & Kolterman, O. G. (2003) · Diabetes Care · doi:10.2337/diacare.26.3.784 · Cited by 307 · cited 1×
“Treatment with the amylin agonist pramlintide has consistently elicited durable weight loss in obese subjects and insulin-using patients with diabetes (2, 12, 26, 27, 39).”
BackgroundSelf-citationRatner, R. E., Dickey, R., Fineman, M., Maggs, D. G., Shen, L., Strobel, S. A., Weyer, C., & Kolterman, O. G. (2004) · Diabetic Medicine · doi:10.1111/j.1464-5491.2004.01319.x · Cited by 307
Self-citationWhitehouse, F., Kruger, D. F., Fineman, M., Shen, L., Ruggles, J. A., Maggs, D. G., Weyer, C., & Kolterman, O. G. (2002) · Diabetes Care · doi:10.2337/diacare.25.4.724 · Cited by 264 · cited 1×
“Treatment with the amylin agonist pramlintide has consistently elicited durable weight loss in obese subjects and insulin-using patients with diabetes (2, 12, 26, 27, 39).”
BackgroundSelf-citationEffect of pramlintide on satiety and food intake in obese subjects and subjects with type 2 diabetes
Chapman, I., Parker, B., Doran, S., Feinle-Bisset, C., Wishart, J., Strobel, S., Wang, Y., Burns, C., Lush, C., Weyer, C., et al. (2005) · Diabetologia · doi:10.1007/s00125-005-1732-4 · Cited by 205 · cited 4×
“Preclinical and clinical studies (7, 20, 32, 40) have provided several lines of evidence to support the hypothesis that the weight-lowering effect of pramlintide is mediated by a reduction in food intake, enhanced meal-related satiation, and improved appetite control.”
BackgroundResultInfluentialSelf-citationBlundell, J. E., & Finlayson, G. (2004) · Physiology & Behavior · doi:10.1016/j.physbeh.2004.04.021 · Cited by 198 · cited 1×
“A person’s tendency to overeat and gain weight may be particularly evident upon exposure to an abundant supply of highly palatable foods (5).”
BackgroundSelf-citationAronne, L., Fujioka, K., Aroda, V., Chen, K., Halseth, A., Kesty, N. C., Burns, C., Lush, C. W., & Weyer, C. (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-2003 · Cited by 178
Self-citationRatner, R. E., Want, L. L., Fineman, M. S., Velte, M. J., Ruggles, J. A., Gottlieb, A., Weyer, C., & Kolterman, O. G. (2002) · Diabetes Technology & Therapeutics · doi:10.1089/15209150252924094 · Cited by 156 · cited 1×
“Treatment with the amylin agonist pramlintide has consistently elicited durable weight loss in obese subjects and insulin-using patients with diabetes (2, 12, 26, 27, 39).”
BackgroundSelf-citation
Cited by
Pharmacological Management of Obesity: An Endocrine Society Clinical Practice Guideline
Apovian, C. M., Aronne, L. J., Bessesen, D. H., McDonnell, M. E., Murad, M. H., Pagotto, U., Ryan, D. H., & Still, C. D. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-3415 · Cited by 1,347
“Pramlintide is an amylin analog that promotes weight loss by increasing satiety and decreasing food intake (65, 66).”
BackgroundRoth, J. D., Roland, B. L., Cole, R. L., Trevaskis, J. L., Weyer, C., Koda, J. E., Anderson, C. M., Parkes, D. G., & Baron, A. D. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0706473105 · Cited by 436
Self-citationAmylin: Pharmacology, Physiology, and Clinical Potential
Hay, D. L., Chen, S., Lutz, T. A., Parkes, D. G., & Roth, J. D. (2015) · Pharmacological Reviews · doi:10.1124/pr.115.010629 · Cited by 400
The Hunger Genes: Pathways to Obesity
van der Klaauw, A. A., & Farooqi, I. S. (2015) · Cell · doi:10.1016/j.cell.2015.03.008 · Cited by 393
Janssen, P., Vanden Berghe, P., Verschueren, S., Lehmann, A., Depoortere, I., & Tack, J. (2011) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2011.04609.x · Cited by 348
Metadata
- Authors
- Smith, S. R., Blundell, J. E., Burns, C., Ellero, C., Schroeder, B. E., Kesty, N. C., Chen, K. S., Halseth, A. E., Lush, C. W., & Weyer, C.
- Venue
- American Journal of Physiology-Endocrinology and Metabolism
- Publisher
- American Physiological Society
- Published
- 2007-08
- Volume
- 293
- Issue
- 2
- Pages
- E620-E627
- ISSN
- 0193-1849 (ISSN-L)
- 1522-1555
- OpenAlex
- W2102695417
- Cited by
- 130
- References
- 10
- FWCI
- 4.56
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Pramlintide treatment reduces 24-h caloric intake and meal sizes and improves control of eating in obese subjects: a 6-wk translational research study. https://app.cochat.ai/papers/10.1152/ajpendo.00217.2007
- The paper
- Smith, S. R., Blundell, J. E., Burns, C., Ellero, C., Schroeder, B. E., Kesty, N. C., Chen, K. S., Halseth, A. E., Lush, C. W., & Weyer, C. (2007). Pramlintide treatment reduces 24-h caloric intake and meal sizes and improves control of eating in obese subjects: a 6-wk translational research study. American Journal of Physiology-Endocrinology and Metabolism. https://doi.org/10.1152/ajpendo.00217.2007
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.